Source: Health Products Regulatory Authority (ZA) Publisher: Strides Pharma SA (Pty) Ltd, 106 16<sup>th</sup> Road, Building 2, Midrand
AMDERIP is indicated for the treatment of depression in adults (18 years and older).
Initially 75 mg to 150 mg daily in divided doses.
Maintenance dose is 50 mg to 100 mg daily in divided doses.
Amitriptyline is for oral use.
The tablets should be swallowed with water.
Overdosage and poisoning may be characterised by central nervous system depression or excitation, severe anticholinergic effects and cardiotoxicity. The signs and symptoms of an overdosage include: drowsiness, restlessness, ataxia, coma, stupor, cardiac dysrhythmias, pyrexia, palpitations, hypotension, tachycardia, convulsions and respiratory depression. Mixed poisoning with other central nervous system depressants is not uncommon. Treatment for overdosage is symptomatic and supportive.
2 years.
Store at or below 25°C.
No special precautions for storage exist for AMDERIP.
AMDERIP 10 are packed in PVC/PVdC/Aluminium blisters containing 30 film-coated tablets. The blister strips are packed in a printed carton.
AMDERIP 25 are packed in PVC/PVdC/Aluminium blisters containing 30 or 60 film-coated tablets. The blister strips are packed in a printed carton.
AMDERIP 50 are packed in PVC/PVdC/Aluminium blisters containing 30 film-coated tablets. The blister strips are packed in a printed carton.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
